Impact of immune suppressive agents on the BK-Polyomavirus non coding control region

Reactivation of the BK-Polyomavirus (BKPyV) can cause a polyomavirus associated nephropathy in approx. 10% of kidney transplant recipients. In these cases, current therapy is based on the reduction of immunosuppression. Since BKPyV-transcription is driven by the Non-Coding-Control-Region (NCCR) we w...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antiviral research 2018-11, Vol.159, p.68-76
Hauptverfasser: Korth, Johannes, Anastasiou, Olympia E., Verheyen, Jens, Dickow, Julia, Sertznig, Helene, Frericks, Nicola, Bleekmann, Barbara, Kribben, Andreas, Brinkhoff, Alexandra, Wilde, Benjamin, Sutter, Kathrin, Dittmer, Ulf, Ciesek, Sandra, Witzke, Oliver, Widera, Marek
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Reactivation of the BK-Polyomavirus (BKPyV) can cause a polyomavirus associated nephropathy in approx. 10% of kidney transplant recipients. In these cases, current therapy is based on the reduction of immunosuppression. Since BKPyV-transcription is driven by the Non-Coding-Control-Region (NCCR) we were interested whether NCCR-activity is affected by immunosuppressive agents. Plasma samples from 45 BKPyV-positive patients after renal transplantation were subjected to PCR-analysis. NCCR-amplicons were cloned into a plasmid that allows the quantification of early and late NCCR-activity by tdTomato and eGFP expression, respectively. HEK293T-cells were transfected with the reporter-plasmids, treated with immunosuppressive agents, and subjected to FACS-analysis. In addition, H727-cells were infected with patient derived BKPyV, treated with mTOR-inhibitors, and NCCR activity was analysed using qRT-PCR. While tacrolimus and cyclosporine-A did not affect NCCR-promoter-activity, treatment with mTOR1-inhibitor rapamycin resulted in the reduction of early, but not late-NCCR-promoter-activity. Treatment with dual mTOR1/2 inhibitors (INK128 or pp242) led to significant inhibition of early, however, concomitantly enhanced late-promoter-activity. In BKPyV infected cells both rapamycin and INK128 reduced early expression, however, INK128 resulted in higher late-mRNA levels when compared to rapamycin treatment. Our results demonstrate that mTOR1-inhibitors are able to reduce early-expression of wildtype and rearranged NCCRs, which might contribute to previously described inhibition of BKPyV-replication. Dual mTOR1/2-inhibitors, however, additionally might shift viral early into late-expression promoting synthesis of viral structural proteins and particle production. •A dual fluorescence reporter was constructed to quantify the non-coding-control-region (NCCR) driven BKPyV gene expression.•NCCRs from patient material obtained after kidney transplantation were amplified and cloned into the reporter plasmid.•The impact of immunosuppressive drugs on the bidirectional BKPyV-promoter activity was analysed.•mTOR1-inhibitors were able to reduce early-expression of archetypical and rearranged NCCRs.•Dual mTOR1/2-inhibitors, however, shifted viral early-into late-expression.
ISSN:0166-3542
1872-9096
DOI:10.1016/j.antiviral.2018.09.013